Who makes HRS9950 tablets?

HRS9950 tablets is developed by Chengdu Suncadia Medicine Co., Ltd..

Last reviewed 2026-04-19 · How we verify

HRS9950 tablets

Chengdu Suncadia Medicine Co., Ltd. · Phase 2 active Small molecule

At a glance

Generic name	HRS9950 tablets
Sponsor	Chengdu Suncadia Medicine Co., Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HRS9950 tablets CI brief — competitive landscape report
HRS9950 tablets updates RSS · CI watch RSS
Chengdu Suncadia Medicine Co., Ltd. portfolio CI